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The enzyme fructose-1,6-bisphosphatase (FBP) is key regula-
tory point in gluconeogenesis. Mutants of Salmonella enterica
lacking purH accumulate 5-amino-4-imidazole carboxamide
ribotide (AICAR) and are unable to utilize glycerol as sole car-
bon and energy sources. The work described here demonstrates
this lack of growth is due to inhibition of FBPbyAICAR.Mutant
alleles of fbp that restore growth on glycerol encode proteins
resistant to inhibition by AICAR and the allosteric regulator
AMP. This is the first report of biochemical characterization of
substitutions causingAMP resistance in a bacterial FBP. Inhibi-
tion of FBP activity by AICAR occurs at physiologically relevant
concentrations and may represent a form of regulation of glu-
coneogenic flux in Salmonella enterica.
An efficient cellular metabolism that can adapt to changing
environmental conditions requires the integration ofmany bio-
chemical pathways. Subtle interactions that exist between
pathways in the metabolic network are in general not well
understood. One level of these interactions involves metabo-
lites common to multiple pathways. Cellular metabolites can
impact physiology through roles in transcriptional regulation,
translational regulation, or by mediating allosteric effects on
key enzymes. One such central metabolite with regulatory
capabilities is 5-amino-4-imidazole carboxamide ribotide
(AICAR).3
AICAR is a purine nucleotide biosynthetic intermediate and
the substrate for AICAR transformylase/IMP cyclohydrolase,
encoded by the purH gene in Salmonella enterica. AICAR is
also generated as a byproduct of histidine biosynthesis, released
by the enzyme imidazole glycerol-phosphate synthase (Fig. 1A).
AICARhas been shown to impact differentmetabolic pathways
in diverse organisms. Bochner and Ames (1) proposed that 5-
amino-4-imidazole carboxamide riboside 5-triphosphate
formed from the accumulation of AICAR is an alarmone for
C1-folate deficiency in S. enterica, although this conclusion, in
its simplest form, was not supported by subsequent work (2).
AICAR has been shown to be a negative effector of cytochrome
terminal oxidase cbb3 production in Rhizobium etli (3) and was
recently shown to affect regulation of purine biosynthesis genes
in Saccharomyces cerevisiae (4). Previous work from our labo-
ratory demonstrated that AICAR accumulation inhibits the
conversion of aminoimidazole ribotide to 4-amino-5-hy-
droxymethyl-2-methyl pyrimidine phosphate in the biosynthe-
sis of thiamine pyrophosphate in S. enterica (5).
Inmammalian systems, AICAR has been shown to activate
AMP-activated protein kinase (6), which plays a critical role
in energy balance and the response to metabolic stress (7).
Through activation of AMP-activated protein kinase,
AICAR inhibits proliferation of several types of cancer cells
(8, 9). Furthermore, AICAR has been shown to inhibit glu-
coneogenesis in mammals due to inhibition of fructose-1,6-
bisphosphatase (10, 11).
Fructose-1,6-bisphosphatase (D-fructose-1,6-bisphosphate
1-phosphohydrolase, EC 3.1.3.11; FBP) catalyzes the hydrolysis
of fructose 1,6-bisphosphate (Fru-1,6-P) to fructose 6-phos-
phate and inorganic phosphate (12). FBP is important for the
regulation of flux between glycolysis and gluconeogenesis (Fig.
1B); as the enzyme is inhibited by AMP and fructose 2,6-
bisphosphate (Fru-2,6-P) (13). Fru-2,6-P is a competitive inhib-
itor with respect to the substrate Fru-1,6-P, which binds at the
active site (14, 15), whereas AMP binds to an allosteric site (16,
17), which causes a structural transition from the active R state
of the enzyme to the inactiveT state (18). FBP frommammalian
sources has been extensively studied at the biochemical level. In
Escherichia coli, FBP activity is required for growth on glycerol,
succinate, or acetate as sole carbon and energy source (19).
E. coli FBP has been shown to be activated by Mg2 and inhib-
ited byAMPandFru-2,6-P, similar to themammalian enzymes,
although Mg2 activation and AMP inhibition did not display
cooperativity, as in the mammalian enzymes (20). The physio-
logical relevance of Fru-2,6-P inhibition of E. coli FBP is not
clear; Fru-2,6-P inhibition is not synergistic with AMP inhibi-
tion as in mammalian systems (20, 21), and to date Fru-2,6-P
has not been found in bacterial cells (22). Phosphoenolpyruvate
has been shown to relieve AMP inhibition of E. coli FBP (21,
23). Recently, the crystal structure of E. coli FBP was reported;
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these authors also demonstrated activation of FBP by phos-
phoenolpyruvate and postulated a novel allosteric binding site
for this compound (24).
The studies described here demonstrate that purH mutants
of S. enterica are unable to use glycerol or other gluconeogenic
carbon sources in the absence of exogenous histidine. Results
show that this growth phenotype is due to inhibition of FBP by
the accumulation of AICAR. AICAR-resistant alleles of fbp
were isolated and the mutant proteins were purified and char-
acterized in vitro. FBP is inhibited by AICAR at physiologically
relevant concentrations and thus this interaction may repre-
sent a form of regulation relevant under some growth condi-
tions, such as folate stress.
EXPERIMENTAL PROCEDURES
Bacterial Strains, Media, and Chemicals
All strains used in this study are derivatives of S. enterica LT2
and are listed with their genotypes in Table 1. The purH355
allele contains a thymidine inserted at position 716, resulting in
a frameshift and generating a truncated PurH protein of 266
amino acids. MudJ refers to the Mud1734 insertion element
(25) and Tn10d(Tc) refers to the transposition-defective mini-
Tn10 described by Way et al. (26). No-carbon E medium sup-
plemented with 1 mM MgSO4 (27, 28) and glucose (11 mM) or
glycerol (22mM)was used as aminimalmedium.Difco nutrient
broth (8 g/liters) with NaCl (5 g/liters) and Luria-Bertani broth
were used as richmedia. Difco BiTek agarwas added (15 g/liter)
for solid medium. When present in the media, supplements
were provided at the following final concentrations: thiamine,
10 or 100 nM; adenine, 0.4 mM; histidine, 74 M.When needed,
antibiotics were added to the following concentrations in rich/
minimal media: tetracycline, 20/10 g/ml; kanamycin, 50/125
g/ml; chloramphenicol, 20/4 g/ml; and ampicillin, 50/15
g/ml. Restriction enzymes and DNA ligase were purchased
from Promega (Madison, WI). Cloned Pfu DNA polymerase
was purchased from Stratagene (La Jolla, CA).
Genetic Methods
Phenotypic Analysis—Nutritional requirements were assessed
on solidmediumwith soft agar overlays and by quantification of
FIGURE 1. A, the purine and histidine biosynthetic pathways in S. enterica. B, glycolysis, gluconeogenesis, and the glycerol utilization pathways in S. enterica.
Gene products catalyzing the reaction are indicated above the relevant steps.
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growth in liquidmedia. Protocols for each have been previously
described (29, 30).
Transduction Methods—The high-frequency generalized
transducing mutant version of bacteriophage P22 (HT105/1
int-201) was used in all transductions (31, 32). Themethods for
transduction and purification of transductants have been pre-
viously described (33).
Isolation of Linked Insertions—Transposons (Tn10d(Tc))
genetically linked to the mutation allowing utilization of glyc-
erol as sole carbon source in a purH mutant were isolated by
standard genetic techniques (34). The chromosomal location of
each insertion was determined by sequencing using a PCR-
based protocol (35, 36). A DNA product was amplified with
degenerate primers and primers derived from the Tn10d(Tc)
insertion sequence as described and sequenced at the Univer-
sity of Wisconsin Biotechnology DNA Sequence Facility.
Molecular Biology Techniques
The fbp gene was amplified from wild-type and mutant
strains using genomic DNA as a template and the forward
primer, 5-TACTTTGCTGGCGCGATTCACCTG-3, and the
reverse primer, 5-TGTTTTCGTTTCCGCCTCATCTGG-3.
The resulting PCR products were purified and ligated into
SmaI-cut pSU19. Plasmids were transformed into E. coli strain
DH5 and screened for vectors containing inserts. The identity
of the resulting plasmids was confirmed by sequencing. Plas-
mids for expression of His-tagged FBP were constructed as
described above using plasmid DNA as the template and the
forward primer 5-GCAGGGAAAGTCATATGAAAACG-3
and the reverse primer 5-CTCGAGCGCGTCCGGGTAT-
TCGCGGATAAA-3 (engineered restriction sites underlined).
These PCR products were ligated into pET20 (Novagen)
digested with NdeI and XhoI and screened as described above.
Plasmids are listed in Table 1.
Purification of FBP
Cultures (10 ml) of DM9297 containing an fbp-expression
plasmid (Table 1), grown overnight in LB with 11 mM glucose,
chloramphenicol, and ampicillin, were used to inoculate 1 liter
of LB with 2.5 mM glucose, chloramphenicol, and ampicillin.
The culture was grown at 37 °C with shaking (200 rpm) to an
optical density at 650 nm of 0.6–0.7 and induced with 1 mM
arabinose. After 3 h at 37 °C, cells were harvested by centrifu-
gation (7000 g, 15min, 4 °C). Cell pellets were resuspended in
15 ml of buffer A (50 mM sodium phosphate, 300 mM NaCl, 50
mM imidazole, pH 7.0) containing protease inhibitor mixture
(Sigma P-8849) and disrupted with a French pressure cell
(15,000 lb/inch2). The crude extract was clarified by centrifu-
gation (39,000 g, for 30min at 4 °C). The clarified extract was
loaded onto a HisTrap FF column (Amersham Biosciences)
equilibratedwith bufferA, then the columnwaswashedwith 15
column volumes of buffer A. Protein was eluted with a linear
gradient (20 column volumes) from 50 to 500 mM imidazole in
buffer A. Fractions containing FBP as judged by SDS-PAGE
analysis were pooled, concentrated to 7–10 mg/ml, exchanged
into buffer B (10 mM potassium phosphate, 20% glycerol, 1 mM
EDTA, 1 mM dithiothreitol, 0.4 mM fructose 1,6-bisphosphate,
pH 7.0), frozen in liquid N2, and stored at80 °C.
Assay of FBP Activity
FBP activity was determined using a coupled, spectrophoto-
metric assay (37). Aliquots of FBP were thawed and diluted to
0.05 g/ml in buffer C (10 mM potassium phosphate, 20% glyc-
erol, pH 7.0) immediately prior to assay. Reactions (1 ml) con-
tained: 100mMTris-Cl, pH 7.5, 0–100M Fru-1,6-P, 0–25mM
MgCl2, 2 mM ammonium sulfate, 0.2 mM NADP, 50 M
EDTA, 5 mM -mercaptoethanol, 0.8 units of glucose-6-phos-
phate dehydrogenase, 0.8 units of phosphoglucose isomerase,
and FBP. Reactions were initiated by the addition of FBP (250
ng), and the reduction of NADP was monitored at 340 nm
(  6.22 mM1 cm1). The linear steady-state portion of the
A340 versus time plot was used to determine the kinetic param-
eters kcat, Km (Fru-1,6-P), and Hill coefficient by fitting initial
velocity data to Equation 1 (R2 0.99),
  Vmax S
H/Km
H	 SH (Eq. 1)
where  is velocity, S is either the concentration of varied cofac-
tor or substrate, Vmax is the velocity at saturating substrate and
cofactor,Km is theMichaelis constant for the varied cofactor or
substrate, and H is the Hill coefficient. The velocity data as
plotted in the double-reciprocal form was fit by the following
function,
y  a 	 bx 	 cx2/1 	 ex (Eq. 2)
where x is 1/[substrate], and y is 1/velocity. The initial slope is
defined as b ae, the slope of the asymptote is c/e, the y inter-
cept is a, and the asymptote intercept is (be c)/e2.
TABLE 1
Strains and plasmids







DM8807 zja8039::Tn10d(Tc) purH355 stm4417-8::Tn10d(Cm) fbp-22
DM8808 zja8039::Tn10d(Tc) purH355 stm4417-8::Tn10d(Cm)
DM8809 zja8039::Tn10d(Tc) purH355 stm4417-8::Tn10d(Cm) fbp-23
DM8810 zja8039::Tn10d(Tc) purH355 stm4417-8::Tn10d(Cm)
DM8811 zja8039::Tn10d(Tc) purH355 stm4417-8::Tn10d(Cm) fbp-24








Plasmids Vector and insert
pMD51 pSU19 (CmR)b; fbp
pMD56 pSU19 (CmR); fbp-22 (T19I)
pMD57 pSU19 (CmR); fbp-23 (G20D)
pMD58 pSU19 (CmR); fbp-24 (T23I)
pMD84 pET20 b()(AmpR)c; fbp
pMD103 pET20 b()(AmpR); fbp-22 (T19I)
pMD104 pET20 b()(AmpR); fbp-23 (G20D)
pMD105 pET20 b()(AmpR); fbp-24 (T23I)
pLysS pACYC184 (CmR)d; T7 gene 3.5e
a SB300A#1 was obtained from J. McKinney (51).
b Construction of pSU19 was described previously (52).
c Plasmid pET20 b() was purchased from Novagen (Madison, WI).
d Construction of pACYC184 was described previously (53).
e Described by Studier (54).
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Inhibition by AMPwas studied by using saturating Fru-1,6-P
(100 M), five concentrations of MgCl2 (0.5–8 mM), and five
concentrations of AMP (0–8 M for FBP(wt), 0–0.6 mM for
FBP(T19I), and 0–8 mM for FBP(G20D) and FBP(T23I)). Inhi-
bition byAICARwas studied by using saturating Fru-1,6-P (100
M), five concentrations ofMgCl2 (0.5–8mM), and five concen-
trations of AICAR (0–120 M for FBP(wt) and 0–10 mM for
mutant FBP enzymes). Inhibition data were fit to the following
equation (Equation 3) for nonlinear mixed-type inhibition (R2
 0.95),
  Vmax S
H/1	 I/Kic Ka	 1	 I/Kiu S
H	 (Eq. 3)
where  is the velocity, Vmax is the velocity with saturating sub-
strate and cofactor with no inhibitor present, Ka is theMichae-
lis constant for Mg2, S is the concentration of Mg2, Kic is the
competitive dissociation constant for inhibitor from the
enzyme-inhibitor complex, Kiu is the uncompetitive dissocia-
tion constant for inhibitor from the enzyme-inhibitor complex,
I is the concentration of inhibitor, and H is the Hill coefficient
for Mg2 derived from Equation 1. Linear and nonlinear
regression analysis was preformed using SigmaPlot 9.0 (Systat
Software).
RESULTS
Salmonella purH Mutants Are Unable to Use Glycerol as a
Sole Carbon and Energy Source—The observation was made
that a purH mutant strain of S. enterica (DM2) was unable to
grow on minimal medium containing glycerol as sole carbon
and energy source and supplemented with adenine and thia-
mine (Table 2). Further experiments demonstrated that this
growth defect was eliminated by the addition of exogenous his-
tidine. This finding led to the hypothesis that the accumulation
of the purine biosynthetic intermediate, AICAR, was inhibiting
an enzyme(s) required for growth on glycerol medium. AICAR
is also generated as a byproduct of histidine biosynthesis; there-
fore addition of exogenous histidine reduces the intracellular
concentration of AICAR in a purHmutant (5).
Mutations That Allow a purH Mutant to Grow on Glycerol
Medium in the Absence of Histidine Map to the fbp Locus—A
purH mutant (DM2) was plated on minimal glycerol medium
supplemented with adenine and thiamine and mutagenized
with diethyl sulfate (3 l spotted in the middle of a plate con-
taining 108 colony forming units). Colonies appeared within
48 h and were concentrated in a ring around the spot of diethyl
sulfate; 24 colonies were purified and re-tested for the glycerol-
positive phenotype. One of these mutants was a purH rever-
tant; and it was discarded. Twelve of the remaining strains were
chosen at random for further study. The causative mutation in
each was found to be genetically linked to a transposon located
near the fbp locus. Six of thesemutants were reconstructed and
the fbp gene was amplified by PCR, cloned into pSU19, and
sequenced. Three unique mutations were identified, causing
the following amino acid substitutions: T19I, G20D, and T23I.
Mutations causing the T19I and T23I substitutions were inde-
pendently isolated multiple times. Isogenic strains containing
each of the three mutations on the chromosome were con-
structed and tested for their ability to grow onminimal glycerol
medium supplemented with adenine and thiamine (Table 2).
The presence of any of these three mutations allowed a purH
mutant to grow on minimal glycerol medium supplemented
with adenine and thiamine. Strains containing null mutations
in fbp also fail to grow on other gluconeogenic carbon sources
such as acetate and succinate (19). In addition to glycerol, purH
mutants failed to use acetate and succinate as sole carbon and
energy sources in the absence of exogenous histidine (data not
shown).
The Mutant FBP Enzymes Are Resistant to Inhibition by
AICAR and AMP in Vitro—Wild-type and mutant FBP
enzymes were purified as His6-tagged fusion proteins via Ni2
affinity chromatography. The purified enzymes were judged to
be 
90% pure by image analysis (Phoretix TotalLab) (Fig. 2).
Kinetic parameters were determined from initial velocity data
for the purified enzymes as described under “Experimental Pro-
cedures.” Fig. 3 shows the  versus substrate concentration for
varying [Fru-1,6-P] (A.1) and [MgCl2](B.1) and the respective
double reciprocal plots (A.2,B.2). These data as illustrated in
the  versus [Fru-1,6-P] and  versus [Mg2] plots are best fit by
a modified Hill equation and the double reciprocal plots show
data that are nonlinear and have a rising trend. This is charac-
teristic of enzymes displaying positive cooperativity. To verify
positive cooperativity,Hill plotswere constructed for the assays
with saturatingMg2 and varied Fru-1,6-P (A.3) and the assays
with saturating Fru-1,6-P and variedMg2 (B.3). Both plots are
linear with a slope (n) corresponding to the Hill coefficient (H)
derived from Equation 1. The kinetic parameters for the wild-
type and variant S. enterica enzymes were derived using Equa-
tion 1 and are listed in Table 3. The values obtained for the
TABLE 2
Mutations in fbp allow purHmutants to grow onminimal glycerol medium in the absence of histidine










DM7596 purH355 WT 73 10 74 2 NGb 70 4
DM7597 WT 71 3 76 2 64 5 68 3
DM7833 fbp-21::MudJ Null 62 6 61 1 NG NG
DM8807 purH355 fbp-22 T19I 63 2 58 4 80 17 78 7
DM8808 purH355 WT 67 6 62 7 NG 84 6
DM8809 purH355 fbp-23 G20D 60 6 60 9 94 10 78 11
DM8810 purH355 WT 68 10 65 7 NG 80 6
DM8811 purH355 fbp-24 T23I 87 3 64 9 92 3 73 7
DM8812 purH355 WT 56 2 71 9 NG 77 4
a Doubling times are calculated from the results of three independent cultures S.D.
bNG, the optical density did not increase during the course of the experiment.
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wild-type enzyme were similar to those reported for the E. coli
enzyme (20).
Inhibition by AMP and AICAR was examined for the wild-
type and variant enzymes. The double-reciprocal plots of the 
versus [Mg2] were found to be nonlinear and inhibition visu-
ally appeared to be competitive relative to [Mg2]. The plots
were nonlinear because of the cooperative behavior of Mg2
binding to the enzymes. Linearity was obtained by raising the
[Mg2] to the power of the Hill coefficient of the specific
enzymes, which was determined using Equation 1 (Table 3). A
representative double reciprocal plot of wild-type FBP inhibi-
tion by AICAR is shown in Fig. 4. The type of inhibition exhib-
ited for AMP and AICAR was determined by graphing initial
rate data in the form of double reciprocal plots at various inhib-
itor concentrations andDixon plots (1/ versus [I]). By compar-
ing actual data to theoretical values obtained by fitting the non-
linear data to various inhibition equations it was found that the
data are best described by Equation 3 formixed-type inhibition.
The inhibition constants are shown in Table 4. This means that
AMP and AICAR bind to both the E and EMg complex. The
high Kiu values and low Kic values obtained from the fits indi-
cated that AMP and AICAR bind more tightly to the free
enzyme and weaker to the EMg complex. Shown in the inset of
Fig. 4 is a replot of the slopes for the theoretical data in Fig. 4
versus [AICAR]1. The relationship is linear indicating that
AICAR and AMP (data not shown) do not inhibit the enzymes
in a cooperative manner. As predicted from the phenotypic
data, all three mutant forms of FBP had significantly higher Ki







Results herein showed that the inability of S. enterica purH
mutants to grow on gluconeogenic carbon sources in the
absence of exogenous histidine is due to inhibition of FBP by
the accumulation of the purine biosynthetic intermediate
AICAR. Revertant mutations restoring growth of the purH
mutant on glycerol mapped to fbp, and resulted in variants of
FBP that were resistant to inhibition by AICAR and AMP.
The three variant proteins characterized in this work
(T19I, G20D, and T23I) had lesions located in the AMP bind-
ing site of the FBP protein as determined from the crystal
structure of the pig kidney enzyme (17). As shown in the
partial alignment in Fig. 5, the AMP binding site is highly
conserved between both bacterial and mammalian enzymes.
S. enterica FBP is 97% identical and 98% similar to E. coli
FIGURE 2. Purification of wild-type FBP-His6 using a HisTrap FF column.
Lane A, molecular weight marker; lane B, crude extract; lane C, clarified crude
extract; lane D, flow-through; lane E, wash; lane F, elution.
FIGURE 3.Kinetic results demonstrate cooperative behavior for Salmonella FBPwhenMg2 and Fru-1,6-P are varied. The plots comparing the velocity
of NADP reduction while varying the concentration of Fru-1,6-P (series A) or Mg2 (series B) are shown. Plots are as follows: 1,  versus [substrate or cofactor]
fit by Equation 1; 2, double reciprocal plot of 1 fit by Equation 2; 3, Hill Plot fit using a linear regression (n slope).
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FBP, 43% identical and 63% similar to the pig kidney enzyme,
and 44% identical and 63% similar to the human liver
enzyme. Like the mammalian enzyme, but unlike the E. coli
enzyme, FBP from S. enterica displayed cooperative kinetic
behavior that had not been reported (mammalian hMg(II)
 2
(38)) (20). Interestingly, S. enterica FBP also displayed coop-
erative behavior for Fru-1,6-P that has not been reported for
any FBP studied to date. Moreover, the S. enterica enzyme
did not show cooperative kinetic behavior for AMP or
AICAR inhibition, whereas this behavior has been shown for
these inhibitors in the mammalian enzyme (mammalian
hAMP  2 (16, 38, 39)).
Thr19 corresponds to Thr27 in the mammalian enzymes; the
side chain of this residue contacts the phosphate group of AMP
in the crystal structure (17), and replacement of Thr27 in the
porcine enzyme with alanine increased the Ki for AMP 1300-
fold (40). In this work, the T19I substitution increased the Kic
for AMP 118-fold and the Kiu 98-fold. Thr23 corresponds to
Thr31 in themammalian enzymes; the side chain of this residue
forms a hydrogen bond with the purine base of AMP in the
crystal structure, and site-directed mutagenesis studies have
confirmed its importance inAMP inhibition (39, 41). Gly20 cor-
responds to Gly28 of the mammalian enzymes, which forms a
hydrogen bond to awatermolecule in theAMPbinding site but
has not been studied by site-directed mutagenesis (42). Addi-
tional residues known to be important in AMP inhibition of the
mammalian enzymes include Arg22, Ala24, Glu29, Ala54, Lys112,
Tyr113, Gly122, and Arg140 (39–41, 43–45). A previous report
on an AMP-insensitive fbpmutant of E. coli found that growth
was unaffected by the presence of thismutation unless the allele
was highly expressed, but further characterization of the
enzyme was not reported (46).
The purine biosynthetic intermediate AICAR was shown to
bind to the AMP binding pocket of human liver FBP by crystal-
lographic studies (42) and shown to inhibit FBP in rat liver
extracts (10, 11). All three substitutions described in this work
significantly reduce inhibition of the enzyme for bothAMP and
AICAR. It is interesting to note that a perfect correlation does
not exist between the effects of each substitution on inhibition
by AMP andAICAR despite the fact that both compounds bind
at the same site. In particular, the T23I substitution increases
theKic for AMP1100-fold, but only increases theKic for AICAR
31-fold. This observation may be explained by crystallographic
data demonstrating that AICAR binds in a slightly different
orientation than AMP; specifically, the imidazole ring of
AICAR is rotated 180° relative to AMP in the crystal structure
(42). The side chain of this residue forms hydrogen bonds to the
FIGURE 4. Inhibition of wild-type Salmonella FBP by AICAR. Double recip-
rocal plots of velocity versus [Mg2]h at 0mM (), 15mM (), 30mM (), 60mM
(‚), and 120 mM (f) AICAR. Lines represent plots of predicted 1/ versus
1/[Mg2] determined using nonlinear regression as described under “Exper-
imental Procedures.” Inset, replot of the slopes of the regression lines versus
[AICAR].
FIGURE 5. Alignment of the N-terminal region of FBP homologs. Black shading indicates 100% conservation; gray shading indicates 50% conservation.
Amino acid substitutions described in this work are indicatedwith letters above the alignment. Positions important for AMP inhibition inmammalian enzymes
are indicated by pound signs. Asterisksmark every 20 amino acids, and the number 6 indicates conservation of a branched chain amino acid or methionine at
that position. The figure was prepared with ClustalX (49) and GeneDoc (50).
TABLE 3
Kinetic parameters for wild-type andmutant FBP enzymes





FBP(wt) 24.3 0.1 10.8 0.4 1.59 0.09 1.75 0.13
FBP(T19I) 26.8 0.7 9.5 0.4 1.70 0.12 1.65 0.11
FBP(G20D) 15.0 1.2 20.1 3.9 1.17 0.18 1.76 0.20
FBP(T23I) 20.4 0.7 8.5 1.1 1.41 0.25 1.37 0.10
TABLE 4
Inhibition constants for wild-type andmutant Fpb enzymes
Parameters are defined under “Experimental Procedures.”
Enzyme KaMg(II)-AICARa KicAICAR KiuAICAR KaMg(II)-AMPa KicAMP KiuAMP
mM M mM M
FBP(wt) 1.3 0.1 37.3 5.6 165 15 2.3 0.2 1.31 0.26 4.14 0.44
FBP(T19I) 2.7 0.3 1700 390 6320 920 2.2 0.3 155 52 404 53
FBP(G20D) 4.4 0.5 2160 510 4610 750 4.6 0.7 1360 340 657 150
FBP(T23I) 1.2 0.1 1160 220 3800 320 2.7 0.3 1450 330 6120 1100
a Ka for Mg2 determined when varying either AICAR or AMP.
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purine ring and a water molecule in the AMP-bound structure,
but in the AICAR-bound structure, the side chain hydrogen
bond to the water molecule is replaced by a backbone nitrogen
hydrogen bond from the sameThr residue. If the substitution of
Ile for this Thr residue still allows the backbone hydrogen bond
while eliminating the side chain hydrogen bond, this could
explain the different effects of this substitution with respect to
the two inhibitors.
The Kic determined for AICAR with the wild-type enzyme
(37.3 5.6M) agrees well with the IC50 determined by Iversen
et al. (42) for the human liver enzyme. This is significant
because it indicates that AICAR inhibits FBP at a physiologi-
cally relevant concentration. Bochner and Ames (47) deter-
mined the intracellular concentration of AICAR in Salmonella
to be 105 M in minimal glucose medium, whereas Rohlman
and Matthews (2) measured concentrations of 40–150 M in
E. coli strain W3110. AICAR has many physiological effects in
various organisms. These data suggest that in enteric bacteria
AICAR has the potential to affect flux through gluconeogene-
sis, as FBP is a key control point for this pathway. The concen-
tration of AICAR would be expected to decrease in response to
exogenous purines or histidine due to feedback inhibition of the
biosynthetic pathways for these compounds. It is known that
AICAR levels increase significantly in response to folate stress
(
3–6-fold) due to inhibition of the PurH enzyme (1, 2).
Genetic evidence suggests that the PurH enzyme is sensitive to
high temperature (48). Considering the in vitro kinetic param-
eters and in vivo pool sizes, it seems likely that flux through
gluconeogenesis may be altered under growth conditions that
impact the concentration of AICAR exemplified by blocking
PurH by mutation.
In summary, the work described here has identified three
amino acid substitutions in FBP from Salmonella that cause
insensitivity to both AMP and AICAR. An additional potential
regulatory role for the small molecule AICAR has been identi-
fied, although further work is necessary to determine whether
this effect is physiologically relevant. Finally, the use of purH
mutants could provide a powerful genetic selection for AMP-
insensitive mutants of FBP, including substitutions that might
not be predicted based on structural information.
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